Dr. Ruemu E. Birhiray, MD

Dr. Birhiray practices at Ascension St. Vincent Hematology and Oncology Indianapolis - Hematology and Oncology - HOPD in Indianapolis, Indiana.

Dr. Birhiray's NPI, 1295735058, was assigned on July 22, 2005. Dr. Birhiray graduated from University of Benin Faculty of Medicine in 1986. Dr. Birhiray's Indiana license number on file is 01053068.

Dr. Birhiray's primary practice is Ascension St. Vincent Hematology and Oncology Indianapolis - Hematology and Oncology - HOPD, at 8301 Harcourt Rd, Indianapolis, IN 46260.

Dr. Birhiray's primary practice is Ascension St. Vincent Hematology and Oncology Indianapolis - Hematology and Oncology - HOPD in Indianapolis, Indiana. Dr. Birhiray is also affiliated with Ascension St. Vincent Hospital - Indianapolis. The medical group on file is Zangmeister Cancer Center. Dmand AI also links Dr. Birhiray to 4 more hospitals, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Birhiray practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Birhiray's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Birhiray is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Birhiray's licenses on file in 4 states: Indiana, Wisconsin, Maryland and Illinois.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Birhiray treats.

CMS data shows 70,207 Medicare services from Dr. Birhiray across 42 procedure codes in 2024, for 1,032 Medicare patients. Medicare paid $1,175,347 for them.

CMS counts 1,032 Medicare patients who saw Dr. Birhiray in 2024. The largest group is 65 to 74, with 497 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Birhiray's median patient age at 72, with 78% women.

In 2024, Dr. Birhiray wrote 2,714 Medicare Part D claims for 608 patients. 71% of them were for generic drugs. CMS names the drug for 2,363 of them, across 47 drugs with 11 or more claims each, at $8,210,013 in total drug cost. In 2023, CMS named 2,239 claims across 47 drugs.

Dr. Birhiray accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 14 papers to Dr. Birhiray, published from 2013 to 2023. 2018 was the busiest year, with 2. The most frequent topics are Multiple Myeloma, Bortezomib and Antibodies, Monoclonal, Humanized. Dr. Birhiray's most frequent co-authors are Suman Kambhampati, MD, Stephen J. Noga, MD and Roger M. Lyons, MD.

Dmand AI links Dr. Birhiray to 6 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating and Carcinoma, Non-Small-Cell Lung. Bavarian Nordic sponsors the most, 2. Open Payments lists research payments to Dr. Birhiray that name 3 trials.

CMS Open Payments shows 5,099 general payments to Dr. Birhiray from 101 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 70% of the total. Janssen Pharmaceuticals, Inc paid the most, $628,529. It also lists 13 research payments totaling $70,252 from 2017 to 2025, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Birhiray, most recently Indianapolis Monthly in 2019.

Dr. Birhiray graduated from University of Benin Faculty of Medicine in 1986. Dr. Birhiray is a member of ASCO.

Dr. Birhiray is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.